AbbVie
FDA warns three Hepatitis C drugs may worsen liver function in some rare cases
August 29, 2019Medical Communications, Research and Development AbbVie, FDA, Gilead, HCV, MSD, hepatitis C, public health
The FDA has warned that three Hepatitis C (HCV) drugs made by AbbVie, Gilead and MSD are worsening liver function …
NHS patients to receive AbbVie’s Skyrizi for plaque psoriasis following NICE recommendation
August 21, 2019Research and Development, Sales and Marketing AbbVie, NICE, Skyrizi, pharma
AbbVie’s Skyrizi (risankizumab) has been awarded a positive recommendation from UK drug watchdog NICE, meaning that the IL-23 inhibitor will …
AbbVie scoops up FDA approval for Rinvoq in moderately to severely active rheumatoid arthritis
August 19, 2019Sales and Marketing AbbVie, FDA, Rinvoq, pharma, rheumatoid arthritis
The FDA has awarded marketing authorisation to AbbVie’s Rinvoq (upadacitinib) for the treatment of moderately to severely active rheumatoid arthritis, …
Humira biosimilar from Samsung Bioepis and MSD wins marketing authorisation in the US
July 24, 2019Research and Development, Sales and Marketing AbbVie, Humira, MSD, Samsung Bioepis, biosimilars, pharma
It’s another victory for MSD as the US drugmaker announced that its biosimilar version of AbbVie’s Humira – the world’s …
Top Ten most popular articles on Pharmafile.com this week
June 28, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Allergan, Bristol-Myers Squibb, China, GSK, Novartis, Takeda, brexit
This week was diverse as always in terms of news coming out of the pharma industry, but the biggest news …
AbbVie poised to acquire Allergan for $63 billion
June 26, 2019Research and Development, Sales and Marketing AbbVie, Allergan, acqusition, pharma
The industry has been rocked with the announcement of another pharmaceutical mega-merger, as it emerged that AbbVie had sealed an …
AbbVie’s Venclyxto combo outclasses chemo in treatment-naive chronic lymphocytic leukaemia
June 5, 2019Research and Development ASCO 2019, AbbVie, Venclyxto, pharma
AbbVie was one of many companies to present new data at this year’s American Society of Clinical Oncology (ASCO) Annual …
AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit
May 20, 2019Research and Development, Sales and Marketing AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failure
AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed …
FDA greenlights Roche and AbbVie’s Venclexta for chronic lymphocytic leukaemia
May 16, 2019Sales and Marketing AbbVie, Cancer, FDA, Roche, Venclexta, leukaemia, pharma
Venclexta (venetoclax), the oral B-cell lymphoma-2 (BCL-2) inhibitor co-developed by AbbVie and Roche, has been approved by the FDA in …
FDA approves AbbVie’s Mavyret for children with Hepatitis C (HCV)
May 1, 2019Research and Development AbbVie, HCV, hepatitis C, mavyret, pharma
The FDA has approved AbbVie’s Mavyret tables (glecaprevir/pibrentasvir) as a treatment for hepatitis C (HCV) in children aged 12 to 17 …
AbbVie’s Skyrizi snatches up FDA approval in moderate to severe plaque psoriasis
April 24, 2019Research and Development, Sales and Marketing AbbVie, FDA, Skyrizi, US, pharma, psoriasis
AbbVie has revealed that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab-rzaa) has received marketing authorisation in the US from the FDA …
Japan awards AbbVie’s Skyrizi with first approval, in 4 psoriasis indications
March 27, 2019Research and Development, Sales and Marketing AbbVie, Japan, Skyrizi, pharma, psoriasis
AbbVie has announced that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has been awarded approval in Japan from the nation’s Ministry …
FDA puts multiple myeloma trial on hold after patient deaths
March 20, 2019Research and Development AbbVie, FDA, Roche, clinical trials, multiple myeloma
The FDA has placed a partial clinical hold on studies of multiple myeloma treatment Venclexta/Venclyxto (venetoclax) following a number of …
Top Ten most popular articles on Pharmafile.com this week!
March 8, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Biogen, Gilead, HIV, Novartis, Scott Gottlieb, top 10
HIV hit the headlines this week after it was announced that a British man known only as the ‘London Patient’ …
AbbVie’s Skyrizi scoops up CHMP recommendation for moderate to severe plaque psoriasis
March 4, 2019Sales and Marketing AbbVie, pharma, psoriasis
AbbVie’s interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has secured recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP), …
Latest content
FibroFind appoints Lee Borthwick as CEO
